Breast cancer is the leading cause of new cancer diagnoses among women. Using peroxisome proliferator-activated receptor (PPAR)c (1=2) mice, we showed normal expression of PPARc was critical to stop 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumorigenesis. PPARc is expressed in many breast cell types including mammary secretory epithelial (MSE) cells. MSEs proliferate as required during pregnancy, and undergo apoptosis or reversible transdifferentiation during involution once lactation is complete. Thus, MSE-specific loss of PPARc was hypothesized to enhance DMBA-mediated breast tumorigenesis. To test this, MSE cell-specific PPARc knockout (PPARc-MSE KO) and control (PPARc-WT) mice were generated, mated and allowed to nurse for three days. One week after involution, dams were treated with DMBA to initiate breast tumors, and randomized on week 7 to continue receiving a normal chow diet (DMBA Only: PPARc-WT, n 5 15; PPARc-MSE KO, n 5 25) or one supplemented with a PPARc activating drug (DMBA 1 ROSI: PPARc-WT, n 5 17; PPARc-MSE KO, n 5 24), and monitored for changes in breast tumor outcomes. PPARc-MSE KOs had significantly lower overall survival and decreased mammary tumor latency as compared to PPARc-WT controls. PPARc activation significantly reduced DMBA-mediated malignant mammary tumor volumes irrespective of genotype. MSE-specific PPARc loss resulted in decreased mammary gland expression of PTEN and Bax, increased superoxide anion production, and elevated serum eotaxin and RANTES, creating a protumorigenic environment. Moreover, PPARc activation in MSEs delayed mammary tumor growth in part by down-regulating Cox-1, Cox-2 and cyclin D1. Collectively, these studies highlight a protective role of MSE-specific PPARc during breast tumorigenesis, and support a novel chemotherapeutic role of PPARc activation in breast cancer.
In 2012, over 250,000 North American women were diagnosed with breast cancer, and over 44,000 died from metastatic complications, with an equally poor prognosis among susceptible men. 1, 2 Advances in early detection and treatment for some types of breast tumors have steadily reduced associated deaths over the last decade, but predicting, which patients will suffer from aggressive forms of disease or respond poorly to current therapy remains a challenge. Interestingly, child-bearing and breast feeding are well known to reduce breast cancer risk, but a transient increased risk of breast cancer following childbirth is also established, 3 which may be due to deregulated interactions between genetic and lifestyle risk factors during mammary gland involution. Improved understanding of these interactions may aid in reducing deaths among susceptible patients.
PPARg is a ligand-activated transcription factor that plays a role in cancer, is essential for adipocyte differentiation, and regulates genes involved in sugar and fat metabolism. 4 PPARg forms a heterodimer with retinoid X receptor (RXR)a and interacts with specific DNA sequences known as peroxisome proliferator-response elements (PPREs) in the promoter regions of a broad range of target genes. 5 In the absence of ligand, the PPARg:RXRa complex associates with cell-specific corepressor molecules that silence target gene transcription. Upon ligand binding, a conformational change leads to the release of corepressors and recruitment of coactivators that promote target gene transcription. Alternatively, ligand activated PPARg may also transrepress gene signaling through direct interaction with other transcription factors or competition for available coregulators. 6 Examples of PPARg ligands include naturally occurring lipids, such as fatty acids and eicosanoids, and a synthetic class of drugs known as the thiazolidinediones (TZDs). 7 Rosiglitazone (ROSI), a TZD and gold standard PPARg activator, improves insulin sensitivity and lowers plasma glucose levels in Type II diabetic patients. 8 PPARg is expressed primarily in adipocytes, 9 as well as many other cell types including mammary epithelial cells, 10 a majority of human breast tumors 11 and breast cancer cell lines. 12 Several in vitro studies reported PPARg ligands promote differentiation and reduce growth in MCF-7 and MDA-MB-231 cells. 12, 13 Others successfully induced in vivo regression of chemically-induced breast tumors in rodents using PPARg ligands. 12, 14, 15 Previously, DMBA-treated PPARg
1=2
mice were shown to be more susceptible to the increased growth and spread of breast, and other tumors as compared to wild-type controls. 16 DMBA-induced breast tumorigenesis was also enhanced by mammary epithelial-directed knock-down of PPARg in vivo. 17 More recently, stromal adipocyte-specific PPARg expression and signaling was also protective in slowing the progression of DMBA-mediated breast tumors. 18 These studies provide direct evidence that normal PPARg expression is critical to suppressing chemical-induced breast carcinogenesis; however, the role of PPARg in other mammary gland-associated cell types remains to be characterized.
The mammary gland undergoes many dynamic changes throughout a woman's lifetime. 19 During pregnancy, the alveolar compartment expands through extensive proliferation of epithelial cells that differentiate to become specialized mammary secretory epithelial (MSE) cells that occupy >90% of the breast and produce milk maximally at lactation. 20 After lactation is complete, the mammary gland undergoes remodeling to a prepregnant-like resting structure wherein these milk-producing cells are cleared by apoptosis. Stromal adipocytes are also capable of transforming into MSE cells as required for pregnancy, and may revert back to their original form after nursing. 20 Since PPARg is essential for fat cell differentiation, 21 it may also be required for this transdifferentiation process. Therefore, it was hypothesized that loss of MSE-specific PPARg postpregnancy may alter normal breast cell function, and increase susceptibility to breast tumorigenesis. Here, it is shown for the first time that loss of PPARg expression in a unique subset of transient-appearing mammary epithelial cells significantly enhances DMBA-mediated breast tumorigenesis, in part by maintaining a protumorigenic environment.
Material and Methods

Animals
All mice were housed and treated in accordance with Canadian Council for Animal Care (CCAC) guidelines under Queen's University Animal Care Committee (UACC)-approved protocols. Animals were housed in microisolator cages throughout a 12 hr light=dark cycle with food and water provided ad libitum. Previously generated PPARg fl=fl (PPARg-WT) mice 16 were crossed with breeders, generously provided by Dr. Hennighausen (NIH, Bethesda), expressing the whey acidic protein (WAP) promoter fused to the Cre Recombinase (Cre) transgene 22 to produce the PPARg fl=fl ; WAP-Cre 1 (referred to here as PPARg-MSE KO) mice. Colonies were maintained by interbreeding for >20 generations. All mice were of mixed C57=6N;SV=129;FVB=N background. Mouse genotypes were confirmed by PCR analysis as described previously. 16 
In vivo carcinogenesis
Eight-week-old PPARg-MSE KO and PPARg-WT female virgin mice were mated with males from respective strains to achieve time-matched pregnancies. Three days following parturition, dams had their offspring removed, and were entered into tumorigenic studies. Prestudy nonfasted submandibular blood was separated to obtain serum samples that were frozen in liquid N 2 for future analysis. One week after the start of involution, breast tumors were initiated in mice from each genotype with 6 individual doses of DMBA by oral gavage weekly, followed by randomization into groups continuing on a normal chow diet or one supplemented with the gold standard PPARg activator ROSI (4 mg=kg=day). Mice were monitored for tumorigenic changes for 25 weeks, and tumor samples were harvested and assessed as previously described.
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Immunoblotting Whole-cell extracts were prepared from normal and tumor tissue samples from PPARg-WT and PPARg-MSE KO mice. Briefly, tissues were homogenized in solubilization buffer, consisting of ddH 2 O, 100 lM sodium orthovanadate, 1M TrisHCl (pH 7.5), 1M MgCl 2, 100 mM PMSF, 73 protease inhibitor, and 10% SDS and then incubated for 1 hr at 4 C. Samples were spun at 15,000g at 4 C for 10 min and the supernatant was collected, flash frozen and stored at 280 C. Protein
What's new?
PPARc is a transcription factor that has been implicated in several types of cancer, including breast cancer. In this study, the authors examined the role of PPARc during breast tumorigenesis in mice, and found that it has a significant protective effect. Drugs that activate PPARc may thus provide a new chemotherapeutic option for breast cancer patients, especially during the postpregnancy period when risk is transiently increased.
concentrations were quantified using the DC protein assay (BioRad 
Immunofluorescent (IF) staining
Sections (5 mm) of formalin-fixed paraffin-embedded involuting mammary glands isolated from untreated PPARg-WT and PPARg-MSE KO females were mounted on slides and incubated at 55 C overnight. Samples were deparaffinized and rehydrated by washing in consecutive dilutions of xylene, ethanol and ddH 2 O. Slides were placed in 1:10 sodium citrate buffer solution (Sigma) at 95 C for 20 min and then trypsinized for 20 min at 37 C. After washing, slides were placed in 0.025% Triton X=TBS buffer solution, followed by a 30 min incubation in 5% BSA/TBS. After washing, primary antibodies (Santa Cruz) for PPARg (sc-7196, 1:500) and b-casein (sc-166520, 1:500) were applied in 5% BSA/TBS for 60 min at room temperature. Slides were rinsed with TBS and then incubated in secondary antibodies for FITC (Santa Cruz, 1:500) and Alexa Fluor 594 (Invitrogen, 1:500) in 5% BSA/TBS for 15 min at room temperature. After a final rinsing regimen with TBS, slides were coverslipped with mounting media containing DAPI stain (Vectashield). IF staining was visualized with a BX51 System Microscope (Olympus) and images were acquired with QCapture Pro 5.1 software (QImaging).
Serum assays
Whole blood was collected from all study mice at one week prior to the start of the DMBA dosing regimen (Week 0), at midstudy (Week 13) and at necropsy. Samples were then centrifuged at 9.8g force for 4.5 min, and serum was collected, flash frozen and stored at 280 C for future study. A Bio-Plex Pro Mouse Cytokine 23-plex serum assay kit (BioRad Laboratories) was used to assess sample cytokine expressions according to manufacturer's protocols. Briefly, beads were washed twice with wash buffer, and serum was diluted 4-fold with the provided dilution solution and incubated with the beads for 1 hr at room temperature. After three washes, beads were incubated with detection antibody for 30 min. The beads were washed again and incubated with streptavidin-phycoerythrin for 10 min before a final wash and resuspension in assay buffer. Samples were read on the Luminex 100 system, and subsequent data analysis was carried out using Bio-Plex Manager 6.0 software. Clustering and heat map analyses were performed with NetWalker 1.0 software. 23 Cytokine concentrations are reported as the mean 6 standard deviation (SD) pg=ml for the following targets: IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17A, eotaxin, G-CSF, GM-CSF, IFN-g, KC, MCP-1, MIP-1a, MIP-1b, RANTES and TNF-a.
Prostaglandin E ELISA
Serum prostaglandin E (PGE) metabolites were analyzed using the PGE Metabolite EIA kit (Cayman Chemical) as per manufacturer's protocol. Briefly, samples were first purified by acetone precipitation, and then derivatized. Using 96-well plates, standards and samples were incubated with PGEM AChE Tracer and EIA Antiserum for 18 hr at room temperature, followed by the addition of Ellman's Reagent. Plates were developed in the dark for an additional 60 min and read at a wavelength of 405 nm. Data are reported as the mean 6 standard error (SE) pg=ml.
Dihydroethidium (DHE) assay
The oxidative fluorescent dye, dihydroethidium (DHE), was used to evaluate in situ production of reactive oxygen species. DHE freely permeabolizes the cell membrane and in the presence of superoxide anion (O 2 2 ) converts to ethidium bromide (EtBr), which remains in the cell by intercalating DNA. Cryofrozen sections (8 lm) of lactating mammary glands from untreated PPARg-WT and PPARg-MSE KO females were coverslipped with a 1:1 mixture of DAPI mounting media and 0.5 mg=ml DHE (Cayman Chemical) and incubated for 30 min at 37 C. Fluorescent staining was imaged by a Quorum WaveFX-X1 spinning disk confocal system (Quorum Technologies) with a Borealis Synapse laser merge module (Spectral Applied Research). Images were collected through a Yokogawa CSU-X1 spinning disk head (field illumination corrected <4%) and two Ludl six position filter wheels with 50 ms adjacent speeds fitted with various emission filters. DAPI was excited with 405 nm and fluorescent emission collected through a 460=50 m filter. Orange EtBr was excited with 568 nm and fluorescent emission collected through a 620=60 m filter. Microscope control and data analysis were performed with Metamorph Offline 7.7 software (Molecular Devices).
Statistical analyses
Data were evaluated for statistical differences using Prism 6.0 software (GraphPad). Comparisons of multiple groups were performed using a Two-Way Analyses of Variance (ANOVA) followed by Tukey's post hoc tests. Incidences were analyzed by Fisher's exact tests. Survival proportions were analyzed by log-rank tests. A p-value of 0.05 was accepted as statistically significant during analysis. deleted specifically in MSE cells from PPARg-MSE KOs (Fig. 1) . Immunoblotting confirmed that PPARg expression is maintained in virgin mammary glands from both PPARg-WT and PPARg-MSE KO strains (Fig. 1) ; whereas, this expression is significantly reduced by three days after initiation of involution in PPARg-MSE KO mammary tissue, a timing that coincides with commencement of our in vivo tumor studies. In addition, as compared to their wild-type controls, untreated PPARg-MSE KO mice are similar in mammary development and nursing ability, and do not have any increased spontaneous breast tumor formation when followed for over 1 year (data not shown), consistent with a report on a similar previously generated strain. 24 This strain is no longer maintained (Dr. Hennighausen, personal communication).
Results
IF analysis of lactating mammary glands shows that
Tumorigenic studies were initiated in postpregnant female mice from each genotype. At week 7, mice were randomized to continue receiving a normal chow diet (DMBA Only: PPARg-WT, n 5 15 and PPARg-MSE KO, n 5 25) or one supplemented with ROSI (DMBA1ROSI: PPARg-WT, n 5 17 and PPARg-MSE KO, n 5 24), and followed for 25 weeks for tumor outcomes. Two PPARg-MSE KO mice treated with DMBA alone and four PPARg-MSE KO mice treated with DMBA1ROSI were found dead in their cage due to undetermined circumstances. These mice were included in survival analyses but their tissues and tumors were excluded from further study due to possible sample degradation.
Throughout the study period, no significant differences were observed among average mouse body weights (Supporting Information Figs. 2a and 2b) or weekly food consumption (Supporting Information Fig. 2c ) between genotypes irrespective of treatment. Analysis of survival proportions among DMBA only-treated mice ( Fig. 2a) showed decreased overall survival among PPARg-MSE KOs, wherein only 50% of animals were still alive by week 17, as compared to similarly treated PPARg-WT mice, which did not reach this plateau even by the end of the observation period (p < 0.05). Similarly, DMBA 1 ROSI-treated PPARg-MSE KO mice showed a strong trend toward decreased median overall survival (Fig.  2b) , reaching a 50% plateau at week 18.5, as compared to similarly treated control mice that did not reach median overall survival by 25 weeks (p 5 0.06). By study end, 53% and 24% of respective DMBA only-treated PPARg-WT and PPARg-MSE KO mice were still alive. Cotreatment with ROSI improved overall survival proportions by 10% in both strains, although this effect was not statistically significant.
Pathological examination of tumors yielded similar incidences of total tumors in DMBA Only-treated PPARg-WTs and PPARg-MSE KOs (percent 6 SE: 87 6 9% vs. 87 6 7%, respectively) and DMBA 1 ROSI-treated strains (88 6 8% vs. 90 6 7%, respectively) (Fig. 2c) . The pattern of DMBAmediated tumor types were consistent with those previously associated with administration of this carcinogen, and comprised mainly mammary tumors, as well as skin, ovarian=uter-ine, thymic, and liver tumors, and lymphomas (Table 1) . When compared to DMBA only-treated PPARg-WT controls, mammary tumor incidences were 2-fold higher among similarly treated PPARg-MSE KO mice, although this was not found to be significant (percent 6 SE: 33 6 12% vs. 61 6 10%, respectively) (Fig. 2d) 2e). In addition, mammary tumor multiplicities between genotypes and across treatment groups showed a consistently higher trend among mice lacking PPARg expression (DMBA only, PPARg-WT vs. PPARg-MSE KO: 1.8 6 0.4 vs. 2.2 6 0.3, respectively; DMBA 1 ROSI: 1.5 6 0.3 vs. 2.3 6 0.5, respectively) but were not significantly different (Fig. 2f) . Interestingly, as compared to similarly treated PPARg-WT mice, DMBA only-treated PPARg-MSE KOs showed a 2-fold increase in the genotypic number of mammary tumors per mouse (mean 6 SE: 0.60 6 0.22 vs. 1.30 6 0.27, respectively); however, these proportions were not significantly altered in either genotype following DMBA1ROSI-treatment (PPARg-WT vs. PPARg-MSE KO: 0.65 6 0.19 vs. 0.80 6 0.28, respectively) ( Table 1 ). In addition, as compared with DMBA onlytreated PPARg-WT littermates, PPARg-MSE KO mice had modestly larger median mammary tumor volumes (PPARg-WT vs. PPARg-MSE KO: 501.0 vs. 567.0 mm 3 , respectively) but these differences were not statistically significant (Fig. 3a) .
When the time to mammary tumor onset was examined, latency was significantly reduced among DMBA only-treated PPARg-MSE KOs, with a median onset by week 19, as compared to PPARg-WT controls that never reached a 50% plateau (p 5 0.05) (Fig. 3b) . DMBA 1 ROSI treatment improved median mammary tumor latency such that by 25 weeks <50% of both mouse strains developed mammary tumors (Fig. 3c) . Given that the majority of treated mouse groups did not reach median survival, quartile (25%) survival time was examined and showed DMBA 1 ROSI-treated mice (PPARg-WT vs. PPARg-MSE KO: week 25 vs. 22, respectively) had an improvement in mammary tumor free survival as compared to DMBA only-treated mice (PPARg-WT vs. PPARg-MSE KO: week 21 vs. 13, respectively). When compared to PPARg-WTs treated with DMBA alone, mammary tumor onset was significantly earlier in DMBA only-treated PPARg-MSE KOs (PPARg-WT vs. PPARg-MSE KO: week 20 vs. 15, respectively; p < 0.01) (Supporting Information Fig. 3 ). In contrast, mammary tumor onset was similar between both genotypes treated with DMBA 1 ROSI (PPARg-WT vs. PPARg-MSE KO: week 20 vs. 18, respectively).
Pathological analysis showed a similar histological pattern of untreated, involuting mammary glands and DMBA-mediated mammary tumor subtypes irrespective of mouse strain or treatment group (Fig. 4 and Table 1 ). Adenocarcinomas and squamous cell carcinomas were the most common mammary tumor subtypes identified. When subclassified by stage and compared to similarly treated controls, the number of tumors per mouse among DMBA only-treated PPARg-MSE KO mice were increased 2-fold for both benign (PPARg-WT vs. PPARg-MSE KO, mean 6 SE: 0. (Table 1 ). In addition, PPARg-WTs had zero metastatic breast tumors per mouse, irrespective of treatment, as Total tumor multiplicity, expressed as a mean 6 SE, was defined as the total number of lesions per tumor-bearing mice for a given genotype and treatment group. (f) Mammary tumor multiplicity was calculated as the number of mammary tumors per mouse afflicted with a breast lesion for a given genotype and treatment group, and expressed as a mean 1 SE. The number of mammary tumors per mouse (multiplicity) is indicated with the total number of these tumors shown in parenthesis. Mammary tumors were also substratified and expressed as multiplicity of benign, malignant and metastatic tumors per genotype and treatment. Examples of specific benign tumor subtypes are also indicated. For nonmammary tissue, the numbers of each tumor per mouse is also indicated with the total number of each shown in parenthesis. Examples of specific tumor subtypes are specified under the title of the tissue type. Finally, total tumors were substratified and expressed as the multiplicity of benign, malignant and metastatic tumors per genotype and treatment.
Carcinogenesis
compared to the modest increased trend for PPARg-MSE KO mice in both DMBA only-treated (0.13 6 0.10) and DMBA 1 ROSI-treated (0.05 6 0.05) groups. To further explore changes in cytokine=chemokine expressions, serum samples were evaluated using a serum cytokine array, with results compared by genotype and treatment group (Table 2 and Fig. 5d ). Untreated PPARg-MSE KO mice showed a significant increase in RANTES concentration as compared to PPARg-WT mice (mean 6 SD: 51.8 6 6.2 vs. 24.7 6 16.4, p < 0.05). For the DMBA 1 ROSI-treated group, PPARg-MSE KO mice showed nonsignificant trends towards higher levels of IL-6 (60.4 6 54.6 vs. 13.4 6 9.7; p < 0.10) and lower levels of IL-12(p40) (728 6 216 vs. 1804 6 958; p < 0.10) as compared to PPARg-WT controls. When analyzed by genotype alone (Supporting Information To further extend our serum findings, the extent of reactive oxygen species production in lactating mammary glands from untreated mice was also assessed using the DHE staining assay. Confocal microscopy (Figs. 5a and 5b) and quantification of EtBr fluorescence (Fig. 5c) , a consequence of O 2
2
-dependent DHE oxidation, revealed that PPARg-MSE KO mice produced significantly more O 2 2 as compared to PPARg-WT controls (Fig. 5c ) (mean 6 SE: 31815 6 381 vs. 24577 6 573, respectively; p < 0.0001).
To assess protein expression changes in proposed PPARg anticancer targets resulting from MSE-cell specific deletion of PPARg, Western blot analyses were performed on untreated involuting mammary glands from each genotype, and malignant mammary tumors from both strains of mice across treatment groups (Figs. 6a and 6b and Supporting Information Fig. 4) . In untreated mammary glands from PPARg-MSE KOs as compared to PPARg-WTs, Bax and PTEN protein expressions were decreased 2-fold, and Cox-1 was decreased 3-fold (Fig. 6a) . When target protein expression changes in mammary tumors from DMBA 1 ROSI-treated PPARg-WTs as compared to DMBA only controls were examined by densitometry, significant 2-fold and 3.5-fold decreases in protein expression of Cox-1 and Cox-2 were observed, respectively (p < 0.05) (Fig. 5b) . In contrast, protein expression of both Cox-1 and Cox-2 among mammary tumors from DMBA 1 ROSItreated PPARg-MSE KO mice increased 1.5-fold as compared to their respective DMBA Only-treated controls. Analysis of 5-lipoxygenase (5-LPO) showed no genotypic or treatment differences. Furthermore, within mammary tumors, DMBA 1 ROSI treatment significantly decreased cyclin D1 expression by 4-fold among PPARg-WTs (p 5 0.05), and nonsignificantly by 1.5-fold among PPARg-MSE KOs as compared to their respective DMBA only-treated groups (Fig. 6b) .
Discussion
The MSE cell-specific role of PPARg in breast tumorigenesis was evaluated. PPARg-MSE KO mice were generated, and had significantly decreased overall survival and shorter mammary tumor latency as compared to PPARg-WT controls. Immunoblotting studies revealed a protumorigenic environment among mammary glands from PPARg-MSE KOs that may contribute to enhanced breast cancer susceptibility. Cotreatment with a PPARg activator provided a greater phenotypic rescue among PPARg-WTs than PPARg-MSE KO mice. The ROSI dose and regimen used in our study is effective in activating PPARg signaling in mice [25] [26] [27] and achieving murine serum profiles in the human therapeutic range. 28, 29 These studies implicate activation of PPARg signaling in subpopulations of mammary gland-specific cells in suppressing carcinogen-induced breast tumors, consistent with our and other studies. 12, 13, 16, 18 Normal PPARg expression was confirmed in virgin mammary glands of both mouse strains, but abolished in MSE cells of PPARg-MSE KO mice from the time of lactation as compared to controls. Accordingly, this knockout model was useful for assessing our hypotheses. The pattern of PPARg expression in a lactating mammary gland was previously implicated in the milk production process, 30 and suggests PPARg is normally expressed at specific times during lactation to suppress inflammatory lipid levels in milk.
Throughout the in vivo tumor studies, DMBA only-treated PPARg-MSE KOs had significantly lower survival rates as compared to PPARg-WT controls. Similar observations were found among DMBA 1 ROSI-treated strains, with modest improvements in overall survival. It cannot be discounted that the rapid growth of breast tumors in these mice and the ethical limitations on tumor study endpoints may have precluded the ability to observe additional carcinogen-mediated micrometastases impacting on vital organs. Further, the influence of tumors arising in nonmammary tissue may have confounded the overall survival results; however, parallel tumor patterns observed in all genotypes and treatment groups suggests that any such contribution is minimal. Together, this data suggests that selective loss of PPARg expression in MSE cells postpregnancy results in reduced overall survival.
That spontaneous tumor formation does not occur in PPARg-MSE KO mice, necessitating DMBA administration to initiate breast tumorigenesis in our animal studies, implies that PPARg acts as a suppressor of tumor progression. Therefore, it was not surprising that parameters of tumor initiation (i.e., mammary tumor incidence and multiplicity) were not different between DMBA only-and DMBA 1 ROSItreated PPARg-WTs and -MSE KOs. While the vast majority of mammary tumors are epithelial in nature, stromal influence on transformed cells may also influence carcinogenesis through signals that prime the tumor microenvironment and fuel disease progression. 31 DMBA-mediated tumorigenesis, and PPARg signaling activation, would be anticipated to exert similar responses in these mammary tumor parameters in both genotypes, which is consistent with the notion that MSE cells do not represent the mammary tumor cell of origin. Pathological sub-classification of mammary tumors also suggested no change in the incidence of mammary tumor malignancy between PPARg-MSE KOs versus PPARg-WT controls. These findings suggest MSE cells lacking PPARg expression affect mammary tumor outcomes in a paracrine fashion rather than serving as primary tumor initiating cells themselves.
Upon examining specific parameters of tumor progression, DMBA only-treated PPARg-MSE KO mice had a significantly earlier mean week of mammary tumor onset as compared to similarly treated PPARg-WT mice. This suggests that loss of PPARg expression in MSE cells decreases mammary tumor latency, presumably through enhanced protumorigenic signaling. This further supports an MSE-specific paracrine influence during early mammary tumorigenesis in PPARg-MSE KO mice. For this tumorigenic measure, it is notable that ROSI cotreatment increased mammary tumor latency among both strains. This suggests activation of signaling within other PPARg-expressing cells associated with, or near, the mammary gland may contribute to this protective effect, and that activation of normal PPARg signaling in other PPARg-expressing cells common to both strains is chemotherapeutic. This is consistent with reports suggesting that, for some parameters, combination antitumor therapies including PPARg activators may be beneficial. 32 Although no genotypic difference in median mammary tumor volumes was observed for either treatment, cotreatment with ROSI significantly decreased pooled malignant tumor volumes versus those from DMBA only-treated mice. This is consistent with studies showing PPARg activation suppresses carcinogen-induced mammary tumor growth in vivo. 14, 15 This was also apparent for the increased benign and malignant mammary tumor multiplicities among DMBA only-treated PPARg-MSE KO mice, which were reduced to levels similar to those observed among PPARg-WTs by ROSI cotreatment. The absence of a genotype-specific effect following ROSI cotreatment suggests that signaling activation within other PPARg-expressing mammary epithelial or stromal cell types in both strains are involved in this protective antitumor effect, consistent with previous findings. 18 Although no genotypic effect was observed with respect to these parameters, this study is the first to examine whether MSE-specific PPARg activation would play a role in this process. Given the number of mammary-associated cell types that express PPARg, such a determination is critical to understand how TZDs may in fact protect against tumorigenesis.
To further characterize the probreast tumorigenic environment promoted by MSE-specific PPARg loss, increased serum eotaxin and RANTES was also observed from PPARg-MSE KO mice. Both of these are chemotactic cytokines that selectively recruit leukocytes to sites of inflammation, and have been linked to the development of human cancer. 33, 34 Deletion of PPARg in MSE cells also increases the pro-breast tumorigenic state of the mammary gland as exemplified by elevated endogenous levels of O 2 2 species in PPARg-MSE KO mice. Reactive oxygen species, like O 2 2 , can alter macromolecular structures and signaling pathways, contributing to oxidative stress, inflammation and carcinogenic progression. 35 Taken together, these findings may be responsible for the increased breast cancer risk observed in PPARg-MSE KO mice.
Involuting mammary tissue from untreated PPARg-MSE KOs exhibit lower levels of Bax and PTEN proteins as compared to PPARg-WTs. This is consistent with previous findings that Bax degradation is mediated by the PI3K pathway, 36 which is opposed by PTEN signaling. Since Bax promotes apoptosis and PTEN is a tumor suppressor, the postpregnant loss of MSE-specific PPARg expression may further contribute to the suggested pro-tumorigenic environment in PPARg-MSE KO mammary glands. This is also consistent with PPARg activation upregulating both PTEN, via a PPRE, and Bax in human MCF-7 breast cancer cell lines. 37, 38 Furthermore, conditional deletion of PTEN in mouse mammary epithelium impairs apoptosis and delays involution. 39 The loss of Bax also impairs cell death early in involution 40 and facilitates tumor progression in mice. 41 Given that the normal inflammatory and proteolytic processes that occur during involution have the capability of transforming the mammary gland microenvironment into one that favors tumorigenesis, 42 disrupting and prolonging the involution program via impaired PTEN and Bax signaling may be responsible for the enhanced susceptibility to tumorigenesis observed among PPARg-MSE KO mice. Schorr et al. 40 also noted partial loss of Bax was most potent in impairing cell death during involution when combined with bcl-2 gain. Coupled with PTEN loss, decreased Bax expression in PPARg-MSE KO postpregnant breast tissue may further delay involution. This effect may have contributed, at least in part, to the enhanced DMBA-mediated breast tumorigenesis among PPARg-MSE KO mice. PPARg activation protects against these effects, albeit more so in PPARg-WT mice, at least in part by suppressing Cox-1, Cox-2 and Cyclin D1.
